PineTree Therapeutics Raised $23.5M for Series A1 Funding

Pinetree Logo

PineTree Therapeutics,  a Cambridge, MA-based biotech company that specializes in therapies in oncology, immuno-oncology and other diseases, raised $23.5M in Series A1 funding.

InterVest, SK Securities and DSC Investment were backers. Samho Green Investment, Samho Green Investment and SJ Investment Partners were also backers.

The company plans to use the funds for their viral disease and oncology platforms.

Led by CEO HoJuhn Song, PineTree Therapeutics is a pre-clinical stage biotech company that has developed the TAER-TAB™ and ViTRAP™ technologies and is building a broad pipeline for hard-to-treat cancers and viral diseases, with an initial focus on oncology.

Get latest news from African Startup ecosystem

Latest stories

You might also like...